You searched for "nAMD"
Atrophy and anti-VEGF
The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...Corporate M&A pace gathers momentum
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...
ABCA1 mediates lipid efflux in the retina
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. There are two forms of AMD, dry and wet, the latter so named because of the presence of choroidal neovascularisation. Both forms lead to retinal pigment...Specialist high-street eye clinics for managing patients with retinal disorders can enhance care standards
The author examines the successful introduction of community-based retinal clinic services by Manchester University NHS Foundation Trust. Dr Sajjad Mahmood, Consultant Ophthalmologist, MREH, shares experience of establishing community-based medical retina clinic services. Sight loss from age-related macular degeneration (AMD), cataract,...
Stereotactic radiotherapy for polypoidal choroidal vasculopathy
Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...
Reduced blood flow and age-related macular degeneration
This was a prospective cross-sectional study assessing changes in blood flow velocity in patients with age-related macular degeneration (AMD) using a retinal function imager. Sixty eyes with wet AMD were compared to 53 control eyes and the average blood flow...Assessing everyday visual function in dry AMD – what matters to the person?
Age-related macular degeneration (AMD) is the primary cause of blindness in the developed world and is accountable for more than one half of sight impairment registrations within England and Wales [1]. AMD is prevalent in people aged 60 years and...Telemedicine strategies in ophthalmology: harnessing established and emerging technologies for lasting solutions
The author considers recent progress and shares insights from leading practitioners in telemedicine applications and digital technology strategies. Amidst COVID-19 and combined mitigation and suppression measures, hospitals and clinics have responded rapidly to strengthen telemedicine strategies and virtual healthcare services...Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...
Visual acuity after cataract surgery in AMD patients
The data from this study are obtained from the Age-Related Eye Disease Study (AREDS) 2 and analysed to evaluate if cataract surgery benefits patients with concurrent age-related macular degeneration (AMD). The AREDS 2 was a five year, prospective, multi-centre randomised...
